MISSISSAUGA, ON, Aug. 18 /CNW/ - AstraZeneca Canada Inc. announced today
that it has filed a New Drug Submission (NDS) for FluMist(R) (Influenza
Vaccine, Live Attenuated Intranasal) with Health Canada. Working in
partnership with its biologics subsidiary MedImmune, AstraZeneca Canada
intends to bring MedImmune's leading vaccine technology to Canadian patients
through its FluMist product, which is administered intranasally. The proposed
indication for FluMist is for the prevention of seasonal influenza.
